Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Lehtinen, Matti; Paavonen, Jorma; Wheeler, Cosette M.; Jaisamrarn, Unnop; Garland, Suzanne M.; Castellsagué, Xavier; Skinner, S. Rachel; Apter, Dan; Naud, Paulo; Salmerón, Jorge; Chow, Song Nan; Kitchener, Henry C; Teixeira, Júlio César; Hedrick, James; Limson, Genara; Szarewski, Anne; Romanowski, Barbara; Aoki, Fred Y.; Schwarz, Tino F.; Poppe, Willy; Carvalho, Newton Sérgio de; Germar, Maria Julieta V; Peters, Klaus; Mindel, Adrian; Sutter, Philippe De; Bosch, F. Xavier; David, Marie Pierre; Descamps, Dominique; Struyf, Frank; Dubin, Gary

doi:10.1016/s1470-2045(11)70286-8

Cited by 595 publications

(504 citation statements)

References 24 publications

Supporting

Mentioning

473

Contrasting

Unclassified

Order By: Relevance

“…Cervical cancer is a classic type of cancer that can be prevented before any cellular changes. The newly introduced Human Papilloma Virus (HPV) vaccine cervical precancerous lesions caused by HPV 16 and 18 is up to 98% (Lehtinen, 2012).…”

Section: Primary Preventionmentioning

confidence: 99%

Gynecological Cancer Services in Arab Countries: Present Scenario, Problems and Suggested Solutions

Ortashi

Kalbani

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Gynecological malignancies account for 9% of all female cancers worldwide. In the Arab countries Breast cancer is the leading cancer in women followed by cervical cancer. Ovarian cancer ranks as fourth leading cancer in women. There are huge differences in the available resources among Arab countries. However the challenges facing the provision of gynecological cancers services shared similarities like the cultural and religious background. Most of the gynecological cancers are diagnosed at a later stage in Arab countries due to the lack of reproductive health awareness especially among older women combined with the cultural stigma of seeking medical advice for gynecological symptoms. This article discusses the current situation of gynecological cancer services in Arab countries and suggests some practical solutions.

show abstract

Section: Primary Preventionmentioning

confidence: 99%

Gynecological Cancer Services in Arab Countries: Present Scenario, Problems and Suggested Solutions

Ortashi

Kalbani

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The high risk HPV types 16 and 18, contribute to about 70% of cervical cancer cases (Smith et al, 2008;Seoud, 2011). Clinical trial studies have demonstrated that two vaccines (Gardasil ® and Cervarix ® ) have almost 100% efficacy in preventing persistent infection and the development of precancerous lesions caused by HPV16 and HPV18 (Kohli et al, 2007;Paavonen et al, 2009;Lehtinen et al, 2012;Schiffman and Wacholder, 2012).…”

Section: Introductionmentioning

confidence: 99%

Human Papillomavirus Vaccination Acceptability among Female University Students in South Africa

Hoque

Ghuman²,

Hal³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The objectives of this present study were to assess the awareness of cervical cancer and its risk factors among female undergraduates in South Africa, and to determine the their level of acceptability of Human Papillomavirus (HPV) vaccination. Materials and Methods: This cross-sectional study was conducted in March 2013 among 440 full time undergraduate female students. Results: Of those students who never had sex (n=163), 96 (58.9%) had ever heard of cervical cancer and only 12 students (12.5%) knew that HPV causes cervical cancer. More than a third (35.4%) of the students correctly said that sexual intercourse before age of 18 years is a risk factor for cervical cancer and 55.2% of the students knew about the Pap smear test which is used for screening cervical cancer. The majority (77.3%) were willing to accept HPV vaccination. Results revealed that students who knew about the Pap smear test, and were aware that having multiple sex partners, sexual intercourse before the age of 18 years, smoking and having contracted any STDs are risk factors for cervical cancer were more likely to accept HPV vaccination compared to other groups. Conclusions: The general knowledge of South African female university students about cervical cancer is not sufficient but they have positive attitudes toward getting vaccinated with the HPV vaccine.

show abstract

“…Randomized trials have shown that both the quadrivalent and bivalent HPV vaccines are highly efficacious in preventing HPV infection, cervical dysplasia, anal dysplasia and in the case of the quadrivalent vaccine, genital warts. [1][2][3][4][5] As part of the introduction of HPV vaccine globally, jurisdictions that started public programs were encouraged to embark on comprehensive monitoring programs to determine HPV vaccine safety, uptake, acceptability and impact of the program on HPV prevalence, cervical dysplasia and ultimately, cervical cancer. 6 Data from Australia, the United States and the United Kingdom have shown that the vaccine is effective, with population level reductions in rates of genital warts, HPV and cervical cancer lesions.…”

mentioning

confidence: 99%

Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis

Naus

Money

Dobson

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

We report on the rates of cervical intraepithelial neoplasia (CIN) in young women aged 15-22 years of age in British Columbia before and after the introduction of an HPV vaccine program. Rates of cervical intraepithelial neoplasia (CIN) 21 for each age stratum (15)(16)(17)(18)(19)(20)(21)(22) in the calendar years 2004-2012 for the province of British Columbia were obtained from the BC Cancer Agency's population-based cervical cancer program. Incidence rate ratios (IRR) of CIN21 were described and compared before and after HPV vaccine program introduction in cohorts born in vaccine eligible years, and in non-vaccine eligible years using piece-wise Poisson regression analysis, and adjusted for age. Between 2004 and 2012, rates of CIN2 and CIN21 in young women aged 15-22 years in the province of British Columbia have decreased overall. After the introduction of the HPV vaccine program, the age adjusted IRR for CIN21 for young women aged 15-17 years decreased significantly from 0.91 (95% CI: 0.86-0.98 p < 0.01) to 0.36 (95% CI: 0.18-0.73 p < 0.01). During the same time period, no similar reduction was found in young women 18-22 years. After introduction of HPV vaccine program, IRR for CIN21 in young women 15-17 was significantly reduced for CIN21 (0.14; 95% CI: 0.04-0.47; p < 0.01) and CIN2 (0.1; 95% CI: 0.02-0.54; p < 0.01). This ecological analysis shows a significant reduction in CIN21 lesions in young women aged 15-17 years in British Columbia after the introduction of the HPV vaccine in young women despite vaccine uptake levels below 70%.The HPV vaccine is one of the most important innovations in cancer prevention. Randomized trials have shown that both the quadrivalent and bivalent HPV vaccines are highly efficacious in preventing HPV infection, cervical dysplasia, anal dysplasia and in the case of the quadrivalent vaccine, genital warts.

show abstract

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Cited by 595 publications

References 24 publications

Gynecological Cancer Services in Arab Countries: Present Scenario, Problems and Suggested Solutions

Gynecological Cancer Services in Arab Countries: Present Scenario, Problems and Suggested Solutions

Human Papillomavirus Vaccination Acceptability among Female University Students in South Africa

Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis

Contact Info

Product

Resources

About